title: Treatment with cinacalcet in 29 kidney transplant patients with persistent hyperparathyroidism.
abstract: OBJECTIVE
  Persistent hyperparathyroidism (HPT) with hypercalcemia and hypophosphatemia is common after renal transplantation, resulting in the need for parathyroidectomy. Cinacalcet may be a therapeutic option for these patients. We sought to analyze the efficacy of treatment with cinacalcet for patients with hypercalcemia (Ca > 10.5 mg/dL) secondary to HPT.
  
  
  METHODS
  We undertook a prospective study of 29 kidney transplant recipients with HPT who started treatment with 30 mg of cinacalcet. The mean follow-up was 13 months (range, 3-29 months).
  
  
  RESULTS
  Treatment with cinacalcet effectively reduced levels of calcium (baseline, 11.1 +/- 0.8 vs 9.7 +/- 0.6 mg/dL at 12 months; P < .05) and intact parathyroid hormone (iPTH; baseline, 288 +/- 155 vs 236 +/- 118 pg/mL at 12 months; P = NS). Phosphorus levels increased from 2.5 +/- 0.6 to 3.2 +/- 0.8 mg/dL (P < .05). The mean dose of cinacalcet was 60 mg (range, 30-120 mg). Two patients required parathyroidectomy. Cinacalcet was well tolerated, except in 2 patients who had nausea and epigastralgia.
  
  
  CONCLUSIONS
  Cinacalcet was safe and effective in kidney transplant patients with hypercalcemia secondary to HPT. Of note was the low incidence of adverse side effects despite the high doses prescribed for these patients.
authors.affiliation: Department of Nephrology, Hospital Universitario Carlos Haya, Málaga, Spain. verolopezjim@yahoo.es
authors.forename: V
authors.initials: V
authors.lastname: López
authors.forename: R
authors.initials: R
authors.lastname: Toledo
authors.forename: E
authors.initials: E
authors.lastname: Sola
authors.forename: C
authors.initials: C
authors.lastname: Gutiérrez
authors.forename: S
authors.initials: S
authors.lastname: Sujan
authors.forename: M A
authors.initials: MA
authors.lastname: Rodríguez
authors.forename: M
authors.initials: M
authors.lastname: Cabello
authors.forename: D
authors.initials: D
authors.lastname: Burgos
authors.forename: M
authors.initials: M
authors.lastname: González Molina
authors.forename: D
authors.initials: D
authors.lastname: Hernández
mesh_terms: D000328:Adult; D000368:Aged; D000069449:Cinacalcet; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy / Q000209:etiology; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000008:administration & dosage / Q000627:therapeutic use*; D016105:Parathyroidectomy; D011446:Prospective Studies; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents; D009281:Naphthalenes; D000069449:Cinacalcet